Ipatasertib: A Comprehensive Guide to its Role as a Pan-Akt Inhibitor in Cancer Therapy
Discover the mechanism of Ipatasertib, a selective pan-Akt inhibitor driving apoptosis in cancer cells.
Get a Quote & SampleProduct Core Value
Ipatasertib
Ipatasertib is a highly selective pan-Akt inhibitor that targets Akt1, Akt2, and Akt3. It plays a crucial role in cancer therapy by inducing p53-independent apoptosis through the activation of the FoxO3a and NF-κB pathways, leading to PUMA upregulation and subsequent Bax-mediated intrinsic mitochondrial apoptosis. Its potential in combination therapies and its in vivo antitumor activity make it a significant agent in oncology research.
- Ipatasertib mechanism of action involves blocking the PI3K/Akt pathway, a key regulator in cancer cell proliferation and survival.
- Ipatasertib cancer therapy has shown promise in various preclinical studies, particularly in colon cancer models.
- Understanding the Akt pathway inhibitors like Ipatasertib is vital for developing targeted cancer treatments.
- The role of PUMA-dependent apoptosis as a mechanism for Ipatasertib's anti-cancer effects is a key finding of recent research.
Key Advantages of Ipatasertib
Selective Akt Inhibition
Ipatasertib exhibits high selectivity for Akt isoforms (Akt1, Akt2, and Akt3), minimizing off-target effects and offering a more refined therapeutic approach compared to less specific inhibitors.
Induction of Apoptosis
The compound effectively triggers programmed cell death (apoptosis) in cancer cells through p53-independent mechanisms, a critical aspect of its anti-tumor activity.
Synergistic Potential
Ipatasertib demonstrates a synergistic effect when combined with other chemotherapeutic agents, enhancing their anti-cancer efficacy and suggesting broader application in combination treatment strategies.
Key Applications
Cancer Therapy
Ipatasertib is primarily explored for its therapeutic potential in treating various types of cancer, particularly those driven by aberrant Akt signaling.
Oncology Research
It serves as a crucial tool in oncology research to unravel the complexities of the PI3K/Akt/mTOR pathway and its role in tumorigenesis and drug resistance.
Biomarker Development
The research suggests that PUMA expression may serve as a biomarker for predicting Ipatasertib's therapeutic efficacy, aiding in personalized medicine approaches.
Targeted Drug Development
Ipatasertib's targeted action makes it a valuable lead compound for the development of next-generation precision cancer therapies.
Related Technical Articles & Resources
Why Choose Us?
Leverage our expertise and state-of-the-art infrastructure to accelerate your journey from discovery to commercial success.
Global Experience
With 20 years of R&D, manufacturing, and sales experience, we proudly serve clients across 60 countries and regions worldwide.
Advanced Facilities
Our in-house R&D laboratory, pilot platform, and large-scale production workshop are equipped to meet the audit requirements of global customers.
Seamless Scalability
We facilitate a perfect transition from small-scale lab requirements (grams) to full commercialization (hundreds of tons).